Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy

Ahmad Rayes, Richard L. Mcmasters, Maureen M. O'Brien

Research output: Contribution to journalArticlepeer-review

66 Scopus citations


Rearrangements of the mixed lineage leukemia (MLL) gene occur frequently in infants with both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Conversions of leukemia cell lineage are rare, but occur most commonly in the setting of MLL-rearrangement. Blinatumomab is a bidirectional antibody targeting CD19 with significant activity in relapsed B-precursor ALL. We report an infant with ALL with t(4;11)(q21;q23) refractory to cytotoxic chemotherapy who was treated with blinatumomab. Following rapid initial clearance of peripheral lymphoblasts, bone marrow evaluation demonstrated a leukemic lineage switch to CD19-negative monoblastic AML. Complete remission was achieved with myeloid-directed chemotherapy.

Original languageEnglish (US)
Pages (from-to)1113-1115
Number of pages3
JournalPediatric Blood and Cancer
Issue number6
StatePublished - Jun 1 2016


  • Blinatumomab
  • CD19
  • Infant
  • Leukemia
  • Lineage
  • MLL


Dive into the research topics of 'Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy'. Together they form a unique fingerprint.

Cite this